Unsurprisingly, the levels of ferroptosis-related biomarkers ACSL4 and COX2 were most significantly elevated in SOR@TF-Fe3+ NVs-treated tumor cells, as determined by qPCR and Western blotting (Fig. 5G and H, for gel source data, see Figure S9, Supporting Information). This evidence concerns the gene PTGS2 and neoplasm.